CY1116520T1 - Φαρμακοτεχνικη μορφη fulvestrant - Google Patents

Φαρμακοτεχνικη μορφη fulvestrant

Info

Publication number
CY1116520T1
CY1116520T1 CY20151100648T CY151100648T CY1116520T1 CY 1116520 T1 CY1116520 T1 CY 1116520T1 CY 20151100648 T CY20151100648 T CY 20151100648T CY 151100648 T CY151100648 T CY 151100648T CY 1116520 T1 CY1116520 T1 CY 1116520T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical form
trienene
pentafluoropentylsulfinyl
estra
diol
Prior art date
Application number
CY20151100648T
Other languages
English (en)
Inventor
John Evans
Rosalind Ursula Grundy
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26243352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116520(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1116520T1 publication Critical patent/CY1116520T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση αναφέρεται σε μία νέα φαρμακοτεχνική μορφή ανεκτής απελευθέρωσης προσαρμοσμένη για να χορηγείται με έγχυση, που περιέχει την ένωση 7α-[9-(4,4,5,5,5-πενταφθοροπεντυλσουλφινυλ)εννεανυλ]οιστρα-1,3,5(10)-τριένιο-3,17β-διόλης, ειδικότερα σε μία φαρμακοτεχνική μορφή προσαρμοσμένη για χορήγηση με έγχυση που περιέχει την ένωση 7α-[9-(4,4,5,5,5-πενταφθοροπεντυλσουλφινυλ) εννεανυλ]οιστρα-1,3,5(10)-τριένιο-3,17β-διόλης σε διάλυμα, σ' ένα όχημα ρικινελαίου, η οποία επιπρόσθετα περιέχει μία τουλάχιστον αλκοόλη κι έναν μη υδατικό εστερικό διαλύτη ο οποίος είναι αναμίξιμος στο όχημα ρικινελαίου.
CY20151100648T 2000-01-10 2015-07-22 Φαρμακοτεχνικη μορφη fulvestrant CY1116520T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0000313.7A GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
EP10180667.7A EP2266573B1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation

Publications (1)

Publication Number Publication Date
CY1116520T1 true CY1116520T1 (el) 2017-03-15

Family

ID=26243352

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100648T CY1116520T1 (el) 2000-01-10 2015-07-22 Φαρμακοτεχνικη μορφη fulvestrant

Country Status (41)

Country Link
US (5) US20030125387A1 (el)
EP (4) EP2266573B1 (el)
JP (3) JP3713237B2 (el)
KR (1) KR100802366B1 (el)
CN (1) CN1222292C (el)
AR (1) AR027510A1 (el)
AT (1) ATE306928T1 (el)
AU (1) AU762080B2 (el)
BE (1) BE1013477A3 (el)
BG (1) BG65776B1 (el)
BR (1) BR0107445B1 (el)
CA (1) CA2351004C (el)
CH (1) CH696260A5 (el)
CO (1) CO5280206A1 (el)
CY (1) CY1116520T1 (el)
CZ (1) CZ304689B6 (el)
DE (2) DE60114145T3 (el)
DK (2) DK2266573T3 (el)
EE (1) EE05421B1 (el)
EG (1) EG24074A (el)
ES (3) ES2543384T3 (el)
FR (1) FR2803516B1 (el)
GB (3) GB0000313D0 (el)
HK (3) HK1049286B (el)
HU (1) HU230162B1 (el)
IL (2) IL150230A0 (el)
IS (1) IS2932B (el)
IT (2) ITTO20010005A1 (el)
MX (1) MXPA02006698A (el)
MY (1) MY118583A (el)
NL (1) NL1017075C2 (el)
NO (2) NO336286B1 (el)
PL (1) PL202525B1 (el)
PT (2) PT2266573E (el)
RU (1) RU2263507C9 (el)
SI (2) SI2266573T1 (el)
SK (1) SK287221B6 (el)
TW (1) TWI259086B (el)
UA (1) UA75879C2 (el)
WO (1) WO2001051056A1 (el)
ZA (1) ZA200204165B (el)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
PL367624A1 (en) * 2001-07-07 2005-03-07 Astrazeneca Ab Pharmaceutical formulation for the intramuscular administration of fulvestrant
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
EP1879587A2 (en) * 2005-04-15 2008-01-23 Schering Corporation Methods and compositions for treating or preventing cancer
US20090227552A1 (en) * 2005-09-26 2009-09-10 Kellie Ann Hooley Fulvestrant formulations
CA2716576A1 (en) * 2008-03-07 2009-09-11 Nageswara R. Palepu Fulvestrant formulations
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
CN102939287B (zh) 2010-06-10 2016-01-27 塞拉根制药公司 雌激素受体调节剂及其用途
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
EP2616078B1 (en) 2010-09-16 2019-12-25 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
CA2836831C (en) 2011-05-20 2015-06-02 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
CN102391341B (zh) * 2011-08-09 2013-05-22 福建省微生物研究所 制备6,7-脱氢-17β-烃酰氧基诺龙的方法
CN103070871B (zh) * 2011-10-26 2015-04-15 正大天晴药业集团股份有限公司 一种氟维司群的药物组合物
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
BR112014014124A2 (pt) 2011-12-14 2017-08-22 Seragon Pharmaceutical Inc Moduladores do receptor de estrogênio fluorados e usos dos mesmos
MX2014007198A (es) 2011-12-16 2014-10-13 Olema Pharmaceuticals Inc Compuestos novedosos de benzopirano, composiciones y usos de los mismos.
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
EP2836199B1 (en) * 2012-04-09 2024-06-19 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP6356218B2 (ja) 2013-04-18 2018-07-11 シーアン リーバン ファーマシューティカル テクノロジー シーオー．， エルティーディー．Ｘｉ’Ａｎ Ｌｉｂａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． 抗腫瘍活性を有する７−α−［９−（４，４，５，５，５−ペンタフルオロペンチルスルフィニル）ノニル］−エストラ−１，３，５（１０）−トリエン−３，１７β−ジオールのエステル誘導体及びその調製方法
WO2014195032A1 (en) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
US20160213682A1 (en) * 2013-09-06 2016-07-28 Salah Uddin Ahmed Fulvestrant compositions
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
AU2015228859A1 (en) 2014-03-13 2016-07-07 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
WO2015179782A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3174542A4 (en) 2014-07-29 2018-01-03 TherapeuticsMD, Inc. Transdermal cream
AU2015367509B2 (en) 2014-12-18 2020-01-02 F. Hoffmann-La Roche Ag Tetrahydro-pyrido(3,4-b)indole estrogen receptor modulators and uses thereof
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR122023020677A2 (pt) 2015-10-01 2023-12-12 Olema Pharmaceuticals, Inc. Compostos de tetra-hidro-1h-pirido[3,4-b]indol, composições compreendendo os referidos compostos e usos dos mesmos
CA3001526A1 (en) 2015-10-13 2017-04-20 Themis Medicare Limited Fulvestrant compositions
RU2747802C2 (ru) 2015-12-09 2021-05-14 Зе Боард Оф Трастис Оф Зе Юниверсити Оф Иллинойс Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
RU2018133932A (ru) 2016-04-01 2020-05-12 Терапьютиксмд, Инк. Фармацевтическая композиция стероидного гормона
CN108883118B (zh) 2016-04-06 2021-06-15 富士胶片株式会社 医药组合物
CN109219604B (zh) 2016-04-08 2021-09-24 豪夫迈·罗氏有限公司 四氢异喹啉雌激素受体调节剂及其用途
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
WO2019094650A1 (en) * 2017-11-08 2019-05-16 Eagle Pharmaceuticals, Inc Fulvestrant formulations and methods of their use
JP2019516789A (ja) * 2016-05-06 2019-06-20 イーグル ファーマスーティカルズ、インク． フルベストラント配合物およびその使用方法
WO2017208847A1 (ja) * 2016-05-31 2017-12-07 富士フイルム株式会社 医薬組成物
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
US20170362228A1 (en) 2016-06-16 2017-12-21 Genentech, Inc. TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
WO2017216279A1 (en) * 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag Heteroaryl estrogen receptor modulators and uses thereof
CN107789320B (zh) * 2016-08-31 2021-06-22 鲁南制药集团股份有限公司 一种氟维司群缓释注射液及其制备工艺
MX2020002649A (es) 2017-09-11 2020-09-25 Atossa Therapeutics Inc Metodos para hacer y usar endoxifeno.
CA3081602A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
CN111465398A (zh) * 2018-01-31 2020-07-28 富士胶片株式会社 注射用制剂的制造方法
RU2684330C1 (ru) * 2018-02-02 2019-04-08 Закрытое Акционерное Общество "Биокад" Композиции фулвестранта
CA3101421A1 (en) 2018-05-24 2019-11-28 Kashiv Biosciences, Llc Prodrugs of fulvestrant
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111035613A (zh) * 2018-10-12 2020-04-21 江苏恒瑞医药股份有限公司 一种包含氟维司群的可注射的药物组合物及其制备方法
EP3873477A4 (en) 2018-11-01 2022-09-07 Syros Pharmaceuticals, Inc. CYCLINE-DEPENDENT KINASE 7 (CDK7) INHIBITORS
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
EP3924054A1 (en) 2019-02-15 2021-12-22 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
PE20220218A1 (es) 2019-05-20 2022-02-02 Novartis Ag Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso
RU2722988C1 (ru) * 2019-11-19 2020-06-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей
CN113260353A (zh) * 2019-12-11 2021-08-13 上海博志研新药物技术有限公司 氟维司群药物组合物、其制备方法及应用
US20230057071A1 (en) 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CA3182346A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CR20230283A (es) 2020-11-24 2023-07-27 Novartis Ag Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
EP4251208A1 (en) 2020-11-24 2023-10-04 Novartis AG Mcl-1 inhibitor antibody-drug conjugates and methods of use
JP2024505562A (ja) 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023121232A1 (ko) * 2021-12-20 2023-06-29 주식회사 삼양홀딩스 용해도가 개선된 풀베스트란트의 약학 조성물 및 그 제조 방법
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB817241A (en) 1957-08-21 1959-07-29 Vismara Francesco Spa Oily solutions for parenteral administration containing adreno-cortical hormones
FR6241E (fr) 1905-04-19 1906-10-10 Ktiengesellschaft Système de refroidissement du piston des moteurs à explosions et des compresseurs
DE947335C (de) 1954-10-19 1956-08-16 Schering Ag Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron
US2983649A (en) 1957-10-15 1961-05-09 Francesco Vismara Societa Per Ricinoleic acid ester solutions of adreno-cortical hormones
GB1060632A (en) * 1962-09-11 1967-03-08 Olin Mathieson Steroid compositions
US3164520A (en) † 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
JPS4327327Y1 (el) 1965-01-07 1968-11-12
NL151903B (nl) 1965-03-24 1977-01-17 Schering Ag Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
USRE28690E (en) * 1965-05-05 1976-01-20 Schering Aktiengesellschaft 17α-Ethinyl-18-methyl-19-nortestosterone esters
GB1207571A (en) * 1967-01-13 1970-10-07 Takeda Chemical Industries Ltd Injectable composition
SU549118A1 (ru) 1973-04-02 1977-03-05 Способ синхронизации половой охоты у циклирующих свиноматок
SU676284A1 (ru) 1975-06-26 1979-07-30 Научно-Исследовательский Институт Животноводства Способ синхронизации половой охоты у самок домашних животных
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
US4048309A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid ointment formulations
NL7711916A (nl) * 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0310542B1 (de) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
JPH04327327A (ja) 1991-04-25 1992-11-16 Toyoda Gosei Co Ltd スリーブとホースの加締め用ダイス
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
DE19510861A1 (de) 1995-03-16 1996-09-19 Schering Ag Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen
US20010006963A1 (en) 1995-03-16 2001-07-05 Ursula Lachnit-Fixson Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
JPH09208496A (ja) * 1996-01-30 1997-08-12 Takeda Chem Ind Ltd Ｌｈ−ｒｈ拮抗物質含有組成物
DE19613972A1 (de) 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
US5952338A (en) 1996-07-05 1999-09-14 Takeda Chemical Industries, Ltd. Agent for prophylaxis and treatment of disturbance of visual function
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19638045A1 (de) 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
JPH10152438A (ja) * 1996-11-22 1998-06-09 Takeda Chem Ind Ltd １−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物
JPH11158200A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd ヒト成長ホルモン・亜鉛複合体及びその用途
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
WO1999027906A1 (en) 1997-12-03 1999-06-10 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated castor oil
EP2266537B1 (en) 1999-04-01 2014-09-03 Hana Biosciences, Inc. Compositions for treating cancer
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP4327327B2 (ja) 2000-04-03 2009-09-09 ロボテック株式会社 固定スプレー揺動装置
PL367624A1 (en) 2001-07-07 2005-03-07 Astrazeneca Ab Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0912999D0 (en) 2009-07-27 2009-09-02 Astrazeneca Ab Method-803

Also Published As

Publication number Publication date
IS2932B (is) 2015-12-15
JP2011190275A (ja) 2011-09-29
GB0000313D0 (en) 2000-03-01
ATE306928T1 (de) 2005-11-15
IS6454A (is) 2002-07-03
EP2266573A1 (en) 2010-12-29
TWI259086B (en) 2006-08-01
PL202525B1 (pl) 2009-07-31
US20050043285A1 (en) 2005-02-24
AU2386301A (en) 2001-07-24
EP2286818B1 (en) 2020-03-18
ES2543384T3 (es) 2015-08-18
JP2003519659A (ja) 2003-06-24
UA75879C2 (en) 2006-06-15
DK1250138T4 (en) 2015-07-27
RU2002121507A (ru) 2004-03-20
SI2266573T1 (sl) 2015-08-31
HK1052884B (zh) 2006-07-14
AR027510A1 (es) 2003-04-02
US8466139B2 (en) 2013-06-18
PT2266573E (pt) 2015-07-28
NL1017075C2 (nl) 2001-09-25
ITTO20010005A0 (it) 2001-01-09
ITTO20010008A0 (it) 2001-01-10
CH696260A5 (de) 2007-03-15
EP1250138B1 (en) 2005-10-19
EP2286818A1 (en) 2011-02-23
ES2248272T3 (es) 2006-03-16
CN1394141A (zh) 2003-01-29
US6774122B2 (en) 2004-08-10
AU762080B2 (en) 2003-06-19
DE60114145T3 (de) 2015-09-17
CZ304689B6 (cs) 2014-09-03
EP2266573B1 (en) 2015-06-17
PT102548A (pt) 2001-07-31
HK1049286B (zh) 2006-04-07
HK1150021A1 (en) 2011-10-28
NO336286B1 (no) 2015-07-13
GB0100407D0 (en) 2001-02-21
HK1049286A1 (en) 2003-05-09
EE05421B1 (et) 2011-06-15
MXPA02006698A (es) 2002-09-30
CN1222292C (zh) 2005-10-12
FR2803516A1 (fr) 2001-07-13
EP1669073A2 (en) 2006-06-14
EP1250138A1 (en) 2002-10-23
US20010020016A1 (en) 2001-09-06
US20030125387A1 (en) 2003-07-03
JP3713237B2 (ja) 2005-11-09
CA2351004C (en) 2003-02-18
RU2263507C2 (ru) 2005-11-10
BE1013477A3 (fr) 2002-02-05
DK2266573T3 (en) 2015-07-20
NO20150741L (no) 2002-07-03
BG65776B1 (bg) 2009-11-30
KR100802366B1 (ko) 2008-02-13
MY118583A (en) 2004-12-31
DE10100779A1 (de) 2001-07-26
SK9842002A3 (en) 2003-05-02
DE60114145D1 (de) 2006-03-02
DK1250138T3 (da) 2006-01-23
DE60114145T2 (de) 2006-07-13
ITTO20010008A1 (it) 2002-07-10
PL356030A1 (en) 2004-06-14
BR0107445B1 (pt) 2012-10-30
EG24074A (en) 2008-05-11
SI1250138T1 (sl) 2006-02-28
HUP0204137A2 (hu) 2003-04-28
IL150230A (en) 2006-10-31
HU230162B1 (hu) 2015-09-28
US20100152149A1 (en) 2010-06-17
SK287221B6 (sk) 2010-03-08
CZ20022384A3 (cs) 2002-09-11
KR20020073499A (ko) 2002-09-26
JP2004107353A (ja) 2004-04-08
CO5280206A1 (es) 2003-05-30
US20120329766A1 (en) 2012-12-27
EP1250138B2 (en) 2015-07-08
WO2001051056A1 (en) 2001-07-19
NO20023227L (no) 2002-07-03
ES2186517B2 (es) 2004-03-16
SI1250138T2 (sl) 2015-09-30
ITTO20010005A1 (it) 2001-07-11
HK1052884A1 (en) 2003-10-03
RU2263507C9 (ru) 2020-07-28
NL1017075A1 (nl) 2001-07-11
CA2351004A1 (en) 2001-07-10
FR2803516B1 (fr) 2003-03-28
NO20023227D0 (no) 2002-07-03
EE200200387A (et) 2003-10-15
IL150230A0 (en) 2002-12-01
GB2359254A (en) 2001-08-22
US8329680B2 (en) 2012-12-11
ES2186517A1 (es) 2003-05-01
BG106833A (en) 2003-03-31
GB0008837D0 (en) 2000-05-31
GB2359254B (en) 2002-06-19
BR0107445A (pt) 2002-09-17
NO337329B1 (no) 2016-03-14
HUP0204137A3 (en) 2005-03-29
ES2248272T5 (es) 2015-08-19
US7456160B2 (en) 2008-11-25
EP1669073A3 (en) 2008-03-19
ZA200204165B (en) 2003-10-29

Similar Documents

Publication Publication Date Title
CY1116520T1 (el) Φαρμακοτεχνικη μορφη fulvestrant
CY1106076T1 (el) Παραγωγα γλυκοπυρανοσυλοξυβενζυλο βενζολιου και ιατρικες συνθεσεις που πepιεχουν τα ιδια
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
BRPI0111639B8 (pt) uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
CY1107142T1 (el) Τυποποιηση που περιλαμβανει fulvestrant
BR0111206A (pt) Derivados de arilmetilamina para uso como inibidores de triptase
CY1105065T1 (el) Φαρμακευτικα μεσα βασιζομενα σε γεσταγονα για δepματικη χρηση
DK1157037T3 (da) GCSF-konjugater
BRPI0400214A (pt) Composições e aplicações farmacêuticas para a obtenção confiável de nìveis aceitáveis de testosterona no soro
NO20026094L (no) Kondenserte azepinderivater og deres anvendelse som antidiuretiske midler
ECSP055629A (es) COMPOSICIÓN QUE CONTIENE UN ESTEROIDE 11ß-HALOGENADO ANDRÓGENO Y UN GESTÁGENO ASÍ COMO UN CONTRACEPTIVO MASCULINO SOBRE LA BASE DE ESTAS COMPOSICIONES
BR0212052A (pt) Preparação de composição farmacêutica de liberação prolongada
AR020032A1 (es) Derivados de 1,3 -metil eritromicina.
PL359624A1 (en) Clear aqueous anaesthetic composition
CY1105168T1 (el) Διφασικη συνθεση με τραμαδολη
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
BR0111729A (pt) 1-aril-4-oxo-1,4-dihidro-3-quinolinacarboxamidas como agentes antivirais
MXPA04000028A (es) Formulacion farmaceutica para la administracion intramuscular de fulvestrant.
CU22836A3 (es) Sistema de gel de nimesulida para uso tópico
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
CY1105798T1 (el) Στepοειδη, η παρασκευη τους, φαρμακευτικες συνθεσεις απο αυτα και χρησεις των ενωσεων
UY27133A1 (es) 11beta-halogenesteroides, su obtención y uso para la preparación de medicamentos y preparados farmacéuticos que contienen 11 beta-halogenesteroides
PA8474401A1 (es) 3-ceto derivados triciclicos de 6-0-metileritromicina
AR012972A1 (es) Forma farmaceutica para la administracion de paclitaxel, proceso para la preparacion de una composicion de paclitaxel lista para usar y uso de estacomposicion
AR026451A1 (es) Compuestos heterociclicos sililados